{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T09:50:52Z","timestamp":1792403452341,"version":"4.4.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T00:00:00Z","timestamp":1560124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T00:00:00Z","timestamp":1560124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s12325-019-00979-6","type":"journal-article","created":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T12:02:42Z","timestamp":1560168162000},"page":"1833-1850","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501"],"prefix":"10.1007","volume":"36","author":[{"given":"Richard","family":"Markus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen J.","family":"McBride","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Ramchandani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Mytych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Fanjiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,10]]},"reference":[{"issue":"6","key":"979_CR1","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/S1074-7613(00)80152-1","volume":"11","author":"FX Pimentel-Muinos","year":"1999","unstructured":"Pimentel-Muinos FX, Seed B. Regulated commitment of TNF receptor signaling: a molecular switch for death or activation. Immunity. 1999;11(6):783\u201393.","journal-title":"Immunity"},{"issue":"7","key":"979_CR2","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/rheumatology\/keq031","volume":"49","author":"T Horiuchi","year":"2010","unstructured":"Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology. 2010;49(7):1215\u201328 (Oxford).","journal-title":"Rheumatology"},{"key":"979_CR3","volume-title":"AMJEVITA (adalimumab-atto) injection for subcutaneous use [prescribing information]","author":"Amgen Inc","year":"2016","unstructured":"AMJEVITA (adalimumab-atto) injection for subcutaneous use [prescribing information]. Thousand Oaks, CA: Amgen Inc, 2016."},{"key":"979_CR4","volume-title":"AMJEVITA (adalimumab) injection for subcutaneous use [summary of product characteristics]","author":"Amgen","year":"2017","unstructured":"AMGEVITA (adalimumab) injection for subcutaneous use [summary of product characteristics]. Breda, The Netherlands: Amgen Europe, 2017."},{"key":"979_CR5","unstructured":"Food and Drug Administration. Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product. \n                    http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM291128.pdf\n                    \n                  . Accessed 3 Aug 2018."},{"key":"979_CR6","unstructured":"European Medicines Agency. Questions and answers on biosimilar medicines (similar biological medicinal products). \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2014\/10\/WC500176768.pdf\n                    \n                  . Accessed 3 Aug 2018."},{"key":"979_CR7","unstructured":"World Health Organization. Guidelines on evaluation of Similar Biotherapeutic Products (SBPs). October 2009. \n                    http:\/\/www.who.int\/biologicals\/areas\/biological_therapeutics\/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf\n                    \n                  . Accessed 3 Aug 2018."},{"key":"979_CR8","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40259-017-0218-5","volume":"31","author":"R Markus","year":"2017","unstructured":"Markus R, Liu J, Ramchandani M, Landa D, Born T, Kaur P. Developing the totality of evidence for biosimilars: regulatory considerations and building confidence for the healthcare community. BioDrugs. 2017;31:175\u201387.","journal-title":"BioDrugs."},{"key":"979_CR9","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s40259-016-0184-3","volume":"30","author":"J Liu","year":"2016","unstructured":"Liu J, Eris T, Li C, Cao S, Kuhns S. Assessing analytical similarity of proposed Amgen biosimilar ABP 501 to adalimumab. BioDrugs. 2016;30:321\u201338.","journal-title":"BioDrugs."},{"issue":"11","key":"979_CR10","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.2217\/imt-2018-0040","volume":"10","author":"J Sivendran","year":"2018","unstructured":"Sivendran R, Ramirez J, Ramchandani M, Liu J. Scientific and statistical considerations in evaluating the analytical similarity of ABP 501 to adalimumab. Immunotherapy. 2018;10(11):1011\u20131021.","journal-title":"Immunotherapy."},{"key":"979_CR11","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40259-016-0185-2","volume":"30","author":"J Velayudhan","year":"2016","unstructured":"Velayudhan J, Chen YF, Rohrbach A, et al. Demonstration of functional similarity of proposed biosimilar ABP 501 to Adalimumab. BioDrugs. 2016;30:339\u201351.","journal-title":"BioDrugs."},{"issue":"5","key":"979_CR12","doi-asserted-by":"publisher","first-page":"S765","DOI":"10.1016\/S0016-5085(17)32654-9","volume":"152","author":"H McBride","year":"2017","unstructured":"McBride H, Kuhns S, Foltz I, Sweet H, Kaur P. ABP 501: matching the critical functions of Adalimumab. Gastroenterology. 2017;152(5):S765.","journal-title":"Gastroenterology."},{"issue":"3","key":"979_CR13","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1136\/annrheumdis-2015-208914","volume":"76","author":"P Kaur","year":"2017","unstructured":"Kaur P, Chow V, Zhang N, Moxness M, Kaliyaperumal A, Markus R. A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab. Ann Rheum Dis. 2017;76(3):526\u201333.","journal-title":"Ann Rheum Dis."},{"issue":"supp 1","key":"979_CR14","doi-asserted-by":"publisher","first-page":"S471","DOI":"10.1093\/ecco-jcc\/jjx180.839","volume":"12","author":"S Doshi","year":"2018","unstructured":"Doshi S, Krishnan E, Wang H, Zhang N, Chow V. Establishing PK equivalence between Adalimumab and ABP 501 in the presence of antidrug antibodies using population PK modeling. J Crohns Colitis. 2018;12(supp 1):S471.","journal-title":"J Crohns Colitis."},{"key":"979_CR15","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.jaad.2016.12.014","volume":"76","author":"K Papp","year":"2017","unstructured":"Papp K, Bachelez H, Costanzo A, et al. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: a randomized, double-blind, multicenter, phase III study. J Am Acad Dermatol. 2017;76:1093\u2013102.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"979_CR16","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1111\/bjd.15857","volume":"177","author":"K Papp","year":"2017","unstructured":"Papp K, Bachelez H, Costanzo A, et al. Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2017;177(6):1562\u201374.","journal-title":"Br J Dermatol."},{"key":"979_CR17","unstructured":"Krishnan E, Wang H, Zhang N. Psoriatic arthritis patient experience with ABP 501 and Adalimumab. In: Presented at European Academy of Dermatology and Venereology (EADV); September 12\u201316, 2018; Paris, France."},{"key":"979_CR18","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1136\/annrheumdis-2016-210459","volume":"76","author":"S Cohen","year":"2017","unstructured":"Cohen S, Genovese MC, Choy E, et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Ann Rheum Dis. 2017;76:1679\u201387.","journal-title":"Ann Rheum Dis."},{"key":"979_CR19","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13075-019-1857-3","volume":"21","author":"S Cohen","year":"2019","unstructured":"Cohen S, Pablos JL, Pavelka K, et al. An open label extension study in rheumatoid arthritis patients to demonstrate long-term safety and efficacy of ABP 501. Arthritis Res Ther. 2019;21:84 .","journal-title":"Arthritis Res Ther"},{"key":"979_CR20","first-page":"318","volume":"77","author":"E Krishnan","year":"2018","unstructured":"Krishnan E, Mytych D, Zhang N, et al. Immunogenicity associated with a transition from adalimumab reference product to ABP 501 in patients with rheumatoid arthritis. Ann Rheum Dis. 2018;77:318.","journal-title":"Ann Rheum Dis."},{"issue":"10","key":"979_CR21","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1373\/clinchem.2005.053272","volume":"51","author":"M Moxness","year":"2005","unstructured":"Moxness M, Tatarewicz S, Weeraratne D, et al. Immunogenicity testing by electrochemiluminescent detection for antibodies directed against therapeutic human monoclonal antibodies. Clin Chem. 2005;51(10):1983\u20135.","journal-title":"Clin Chem."},{"key":"979_CR22","doi-asserted-by":"publisher","first-page":"3072586","DOI":"10.1155\/2016\/3072586","volume":"2016","author":"S Song","year":"2016","unstructured":"Song S, Yang L, Trepicchio WL, Wyant T. Understanding the supersensitive anti-drug antibody assay: unexpected high anti-drug antibody incidence and its clinical relevance. J Immunol Res. 2016;2016:3072586.","journal-title":"J Immunol Res."},{"key":"979_CR23","unstructured":"Kaur P, Cohen S, Papp K, et al. ABP 501 (AMJEVITA\u2122) Biosimilar to Adalimumab: demonstration of value with lower perception of injection site pain. In: Presented at the Academy of Managed Care Pharmacy Annual Meeting; March 27\u201330, 2017; Denver, CO."},{"key":"979_CR24","unstructured":"Krishnan E, Zhang N, Wang H. Injection site reactions and injection site pain for the Adalimumab biosimilar ABP 501: results from two double-blind randomized controlled studies. In: Poster presented at European Crohn\u2019s and Colitis Organization (ECCO) Congress; February 14\u201317, 2018; Vienna, Austria."},{"issue":"2","key":"979_CR25","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/j.1742-7843.2006.pto_271.x","volume":"98","author":"T Laursen","year":"2006","unstructured":"Laursen T, Hansen B, Fisker S. Pain perception after subcutaneous injections of media containing different buffers. Basic Clin Pharmacol Toxicol. 2006;98(2):218\u201321.","journal-title":"Basic Clin Pharmacol Toxicol."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-00979-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-019-00979-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-00979-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T23:12:12Z","timestamp":1591657932000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-019-00979-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,10]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["979"],"URL":"https:\/\/doi.org\/10.1007\/s12325-019-00979-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,10]]},"assertion":[{"value":"21 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}